PIPELINE
We target autoinflammatory and autoimmune diseases with high unmet medical need for which only limited treatment options exist. This includes Graft-versus-Host Disease (GvHD) and autoimmune diseases.
CELL THERAPIES
Development
Preclinical
Phase 1
Phase 2
Phase 3
BIOLOGICS
Development
Preclinical
Phase 1
Phase 2
Phase 3
ATreg/Actileucel (ATX-002)
(prevention of GvHD)
Allogeneic cell therapy.
A Phase Ib/II clinical trial evaluating the safety and feasibility of ATreg/Actileucel (ATX-002) early after HSCT has been completed across four clinical sites in Germany.
First signs for efficacy: No Grade 3-4 aGvHD, 10% Grade 2-4 aGvHD and no non-relapse mortality.
ATreg/Actileucel (ATX-002) has received orphan drug designation (ODD) for use after stem cell transplantation by EMA and FDA.
ATreg/Actileucel (ATX-002)
(treatment of autoimmune diseases)
Allogeneic cell therapy.
Treg are known to have tissue-reparing capability and to have positive impact on autoimmune diseases.
With own research ActiTrexx has gathered comprehensive data to support the application of ATreg/Actileucel (ATX-002) for the treatment of autoimmune diseases.
Biologic
ATX-003
Biologic.
The recombinant protein ATX-003 binds to CD4 and specifically activates Treg.
ATX-003 is being developed for in-vivo activation of the patient’s own Treg to treat autoimmune diseases in combination therapy.
It strongly enhances the efficacy of disease-modifying drugs (DMDs).
The preclinical development is ongoing.